Advancements in mRNA Encoded Antibodies for Passive Immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Monoclonal antibodies represent a rapidly expanding therapeutic category with broad applications.
• Current antibody production faces significant manufacturing and purification challenges, leading to high costs and extended production timelines.
• Alternative, more efficient production platforms are actively being explored.

Purpose of the Study:

• To review the feasibility of using messenger RNA (mRNA) for in vivo antibody production.
• To examine preclinical and clinical evidence supporting mRNA-encoded antibodies.
• To discuss the challenges and future outlook for this therapeutic modality.

Main Methods:

• Review of existing preclinical studies on mRNA-encoded antibodies.
• Analysis of clinical trial data for mRNA-based antibody therapeutics.
• Evaluation of the advantages of in vivo mRNA expression for antibody generation.

Main Results:

• Messenger RNA (mRNA) has emerged as a viable platform for encoding and producing proteins, including antibodies, in vivo.
• Preclinical and clinical studies demonstrate the potential of mRNA-encoded antibodies.
• In vivo expression via mRNA offers distinct advantages over traditional recombinant antibody production.

Conclusions:

• mRNA-encoded antibodies present a promising alternative to conventional antibody manufacturing.
• This technology has the potential to reduce costs and lead times, enhancing therapeutic accessibility.
• Further research is needed to address remaining challenges for widespread clinical adoption.